Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation

(University of Pennsylvania School of Medicine) A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.